Glenmark Pharmaceuticals Peer Comparison
NSE: GLENMARK | BSE: 532296
₹2,441.50
₹115.80
(4.98%)
As on 29-Sep-2026 15:59IST
Market cap
₹67,026 Cr
Revenue (TTM)
₹17,737 Cr
P/E Ratio
37.3
P/B Ratio
6.1
Div. Yield
0.1 %
Edit
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
67,026 | 1,08,560 | 35,667 | 28,005 | 26,243 |
Revenue (₹ Cr) |
17,737 | 7,270 | 3,564 | 9,205 | 1,936 |
Net Profit (₹ Cr) |
1,797.81 | 1,090.76 | 414.00 | -371.81 | 288.22 |
Net Margin (%) |
9.86 | 14.89 | 11.23 | -3.93 | 14.79 |
RoE (%) |
30.87 | 21.64 | 8.38 | -3.85 | 29.77 |
Price to Earnings |
37.28 | 99.29 | 87.21 | -- | 91.06 |
Price-To-Book |
6.11 | 19.25 | 7.08 | 3.50 | 19.55 |
Income Statement (₹ Cr)
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Operating Revenue
|
17,736.55 | 7,269.64 | 3,564.00 | 9,205.28 | 1,935.80 |
|
Total Income
|
18,236.50 | 7,323.34 | 3,686.00 | 9,449.59 | 1,948.58 |
|
Total Expenditure
|
12,939.86 | 5,235.79 | 2,792.00 | 8,195.15 | 1,485.56 |
|
EBITDA
|
4,796.69 | 2,033.85 | 772.00 | 1,010.13 | 450.24 |
|
Depreciation
|
616.73 | 487.08 | 226.00 | 857.51 | 50.83 |
|
EBIT
|
4,179.96 | 1,546.77 | 546.00 | 152.62 | 399.41 |
|
Interest
|
204.50 | 161.45 | 217.00 | 342.73 | 40.84 |
|
Other Income
|
499.94 | 53.70 | 122.00 | 244.31 | 12.78 |
|
Exceptional Items
|
-1,942.85 | 0.00 | 12.00 | -216.88 | 0.00 |
|
Profit before Tax
|
2,532.56 | 1,439.02 | 463.00 | -162.68 | 371.35 |
|
Provision for Tax
|
734.75 | 348.26 | 49.00 | 209.13 | 83.14 |
|
Profit after Tax
|
1,797.81 | 1,090.76 | 414.00 | -371.81 | 288.22 |
Liabilities (₹ Cr)
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
10,512.11 | 5,300.06 | 4,940.00 | 8,162.62 | 1,288.82 |
|
Minority Interest
|
0.10 | 2.84 | -5.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
3,019.66 | 1,444.40 | 1,712.00 | 5,044.14 | 202.03 |
|
Current Liabilities
|
6,376.43 | 3,635.43 | 1,622.00 | 4,758.28 | 835.87 |
|
Total Liabilities
|
19,906.65 | 10,511.19 | 8,578.00 | 17,723.32 | 2,326.71 |
Assets (₹ Cr)
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
7,567.18 | 5,220.48 | 5,343.00 | 10,211.52 | 519.60 |
|
Current Assets
|
11,299.71 | 4,829.21 | 2,606.00 | 7,191.66 | 1,681.81 |
|
Total Assets
|
19,906.65 | 10,511.19 | 8,578.00 | 17,723.32 | 2,326.71 |
|
Total Debt*
|
0.00 | 2,397.49 | 2,125.00 | 5,495.48 | 259.37 |
|
Net Current Assets
|
4,923.28 | 1,193.78 | 984.00 | 2,433.38 | 845.94 |
|
Contingent Liabilities
|
787.81 | 420.55 | 768.26 | 95.72 | 19.09 |
Cashflow (₹ Cr)
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
3,445.03 | 1,623.50 | 390.00 | 1,652.60 | 205.05 |
|
Cash Flow from Investing Activities
|
-1,283.23 | -1,088.66 | -241.00 | -826.03 | -409.72 |
|
Cash from Financing Activities
|
-2,708.75 | -524.72 | -54.00 | -38.98 | 283.07 |
|
Net Cash Inflow / Outflow
|
-546.95 | 10.12 | 95.00 | 787.59 | 78.39 |
Ratios
Profitability Ratios
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
ROCE (%)
|
20.35 | 18.20 | 6.79 | 1.24 | 29.22 |
|
ROE (%)
|
30.87 | 21.64 | 8.38 | -3.85 | 29.77 |
|
ROA (%)
|
10.00 | 10.99 | 4.94 | -2.21 | 24.77 |
|
EBIT Margin (%)
|
23.57 | 21.28 | 15.32 | 1.66 | 20.63 |
|
Net Margin (%)
|
9.86 | 14.89 | 11.23 | -3.93 | 14.79 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
32.94 | 22.62 | 18.37 | 0.78 | 46.65 |
|
EBIT Growth (%)
|
126.49 | 87.41 | 252.26 | -70.53 | 62.13 |
|
Net Profit Growth (%)
|
138.48 | 116.73 | 377.85 | -1,383.43 | 89.49 |
|
EPS Growth (%)
|
174.53 | 114.66 | 1,001.33 | -484.84 | 78.60 |
|
Book Value Growth (%)
|
18.53 | 18.63 | 13.47 | 0.33 | 144.31 |
Valuation Ratios
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Price / Earnings
|
21.26 | 99.37 | 89.19 | -87.84 | 89.86 |
|
Price / Book Value
|
6.01 | 19.28 | 7.06 | 3.43 | 19.60 |
|
Dividend Yield (%)
|
0.11 | 0.10 | 0.00 | 0.00 | 0.09 |
|
EV/EBITDA
|
13.50 | 54.57 | 47.93 | 31.31 | 58.23 |
|
Market Cap (₹ Cr)
|
60,201.30 | 53,545.31 | 19,071.62 | 18,108.89 | 12,753.19 |
Solvency Ratios
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.12 | 0.31 | 0.53 | 0.11 |
|
Short term debt to equity ratio
|
-- | 0.28 | 0.09 | 0.09 | 0.05 |
|
Current Ratio
|
1.77 | 1.33 | 1.61 | 1.51 | 2.01 |
|
Quick Ratio
|
1.23 | 0.68 | 1.06 | 0.87 | 1.14 |
|
Interest Coverage
|
13.38 | 9.91 | 3.13 | 0.53 | 10.09 |
Operating Efficiency Ratios
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
27.98 | 29.64 | 16.50 | 23.44 | 26.28 |
|
Asset Turnover
|
0.99 | 0.73 | 0.43 | 0.55 | 1.66 |
|
Receivable days
|
43.78 | 111.49 | 58.75 | 78.20 | 40.13 |
|
Inventory Days
|
34.05 | 114.62 | 75.82 | 93.30 | 60.29 |
|
Payable days
|
264.58 | 155.13 | 186.21 | 226.14 | 232.47 |
|
Cash Conversion Cycle
|
-186.74 | 70.98 | -51.64 | -54.64 | -132.04 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
